Carter has been a cannabis professional in Colorado since January 2014. His experience over the past five years has been wide ranging and has included political action, state congressional testimony, receiving investment, entrepreneurship, business acceleration, and establishing himself as "The Pot Scientist" YouTube personality by uploading hundreds of videos. He is now happily employed as a R&D technician for a growing late-stage CBD startup in Golden, Colorado.View the profile
Dr. Anna Schwabe recently received her PhD from the University of Northern Colorado where she used a genetic approach to assess sources of variation. She recieved both the Dean's Citation for Academic Excellence as well as the award for Outstanding Dissertation. Her research focused on genetic relationships in various Cannabis groups, as well as how genotypic variation in retail Cannabis is reflected in phenotypic characteristics. Her first Cannabis manuscript examining genetic variation within retail strains in the first edition of the Journal of Cannabis Research has been well received, and her second manuscript examining genetic relationships among common Cannabis usage groups is currently in review. She is now coordinating research projects at Mile High Labs and aims to assist in creating consistency in Cannabis products.View the profile
Julie Fry has extensive experience in quality control compliance and regulatory standards for the acquisition, manufacturing, and production of pharmaceutical and food grade materials, including Cannabis. Her experience includes a comprehensive understanding of the processes involved in the derivation and implementation of a variety of International Organization for Standardization standards (ISO 13485:2016, 22000:2018, 17025:2017, 9001:2015), as well as ASTM, PFC, GMP, GLP, GAP, and GCP protocols. Ms. Fry has worked in many different laboratory settings, both in academia and within the biotechnology and Cannabis industries, and because of this, uniquely understands how to take a product from bench-top to market correctly. She graduated from The Virginia Polytechnic Institute and State University (Virginia Tech) with a bachelor's degree in Biology, with a minor in Chemistry. Ms. Fry then obtained a master's degree in Biochemistry from the Swiss Federal Institute of Technology (Eidgenössische Technische Hochschule, Zürich). She is also a subject matter expert (technical English) editor as well as a cannabis science consultant and education liaison. She is currently a member of the ASTM’s D37 Cannabis Technical Committee, tasked with drafting universal Cannabis standards and best practices, as well as a member of the ACS’s CANN, the Cannabis chapter of the American Chemical Society.View the profile
Born and raised in Colorado, Sean’s career began at the University of Colorado, where he obtained a bachelor’s degree in chemistry and biochemistry researching enzyme-activated anti-cancer drugs. His studies ultimately took him to New Haven, CT, where he earned a PhD in organic chemistry from Yale University, focusing chiefly on the development of oxidation methodology using aspartyl-peptide catalysts.View the profile
Dr. Towle has been an active participant in the cannabis industry for over 5 years. He has been a volunteer for the Cannabis Chemistry Subdivision within the American Chemical Society, participating as networking event coordinator, secretary of the executive committee, and session chair for the 258th National Meeting. He has developed methods for cannabis analysis, extraction, and purification. In fact, Dr. Towle holds a patent on cannabis extraction using ethyl acetate as a solvent (US Patent # 9,937,218). Currently, Dr. Towle is advancing cannabis science and research as Director of Chemistry at MedPharm Holdings.View the profile
About the talk
The Others: Your eyes don't deceive you. This is a CBD Expo, but there are many more therapeutic molecules in hemp, including so-called minor cannabinoids like CBC, CBN, and CBG. Many consumers of hemp products are not after CBD isolates; rather, they are seeking the full molecular ensemble that the plant has to offer. While the scientific evidence may be lacking, anecdotal patient feedback has demonstrated that many people just feel better when complementary cannabinoids are present in the products they use. This panel will shed light on what these other cannabinoids can do from a medical perspective, and why some, like CBC, are being touted as highly important.
00:20 Speaker introductions
05:52 Insights on CBC
09:43 More about CBN
10:13 CB1 and CB2 receptors
13:35 THC decarboxylation for out of brain receptors
15:03 Thoughts on CBG
18:48 Is there a higher percentage of CBG earlier in the flowering process?
20:40 Creation of other cannabinoids
24:10 THC centered cannabis - Moonshine of cannabis
29:00 Thinking of individual cannabinoids or ratios?
31:36 Blood test of the endocannabinoid system
34:40 TRP receptors
35:37 Single molecules as research tools
39:00 Universities and cannabis
44:17 Summary of the talk
Included in subscription
Welcome to the CBC, CBN, CBG, and more panel. Discussions about what are these molecules. How can we get them? What is the future that we can pray for all profits up here? We can tell what will come of what don't we know that is the core of science is the unknown so paneled introduce yourselves your name your maybe profession you're in cannabis and what you want to bring to this discussion. Alright, I'm Dr. Tyrell Towle. Ph.D. in you could bring that closer to medicinal natural products chemistry from the University of Iowa.
So I've actually been working in cannabis for about 5 just over 5 years. Now. I got started in Washington state just after Colorado and Washington state had legalized adult-use cannabis. I worked initially on novel extraction methods, which led to a patent on F last hit extraction of cannabis. I also worked in a cannabis quality assurance laboratory for a year-and-a-half. So 2 years I've been at Med pharm Holdings, which is vertically integrated. Manufacturer here in Colorado. So we grow